A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
This is a multicenter, randomized, double-blind, placebo-controlled Phase II platform study to investigate the efficacy and safety of several interventions in participants with moderate to severe AD.
The first intervention planned to be evaluated is GHZ339. Participants will be randomly assigned to one of the study arms.
Key Inclusion Criteria of the master protocol:
Key Exclusion Criteria of the master protocol:
Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements
novartis.email@novartis.com1-888-669-6682
+41613241111
Caba, Buenos Aires C1119ACN, Argentina
Caba, Buenos Aires C1121ABE, Argentina
Plzen Bory, 301 00, Czechia
Shinagawa Ku, Tokyo 1418625, Japan
Las Palmas GC, 35010, Spain